Publication: 3764

Publication: 3764

CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Cancer Res Commun vol 4 (3) 682-90

Year:: 2024
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 13

Parents:: 3431
Children:: None

Program:: OGC
Primary Committee:: GI
Sec. Committees:

Pharmas:: Bayer, Bristol-Myers-Squibb, and Sanofi
Grants:: U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA233253, UG1CA233290, UG1CA233327, UG1CA233373, U10CA180863 (CCTG), U10CA180820 (ECOG-ACRIN), U10CA189859, U10CA180888 (SWOG)

Corr. Author:
Authors:: Ghassan K. Abou-Alfa Susan M. Geyer Andrew B. Nixon Federico Innocenti Qian Shi Priya Kumthekar Sawyer Jacobson Imane El Dika Amin Yaqubie Juan Lopez Binhui Huang Yi-Wei Tang Yujia Wen Lawrence H. Schwartz Anthony B. El-Khoueiry Jennifer J. Knox Lakshmi Rajdev Monica M. Bertagnolli Jeffrey A. Meyerhardt Eileen M. O'Reilly Alan P. Venook

Networks:: CA011, CA824, LAPS-IL036, LAPS-MA036, LAPS-NC007, LAPS-NC010, LAPS-NY016, MN022, NY021

Study: CALGB-80802
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: Research Article, Gastrointestinal Cancers, Liver Cancer, Translational Research, Small Molecule Agents, Kinase inhibitors, Topoisomerase agents, DNA-reactive agents, Chemotherapy, Combination Chemotherapy, Clinical-Stage Research, Clinical Trial Results, Phase III clinical trials